Cancer Immunology, Immunotherapy

, Volume 56, Issue 6, pp 761–770 | Cite as

Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2

  • Kousaku Mimura
  • Koji Kono
  • Akihiro Takahashi
  • Yoshihiko Kawaguchi
  • Hideki Fujii
Original Article


Dendritic cells (DCs) are the most potent antigen-presenting cells and play a central role in the host-antitumor immunity. Since it has been reported that vascular endothelial growth factor (VEGF) inhibits the functional maturation of immature-DCs and impairs DC differentiation, it is important to elucidate the mechanisms of VEGF-induced DC-dysfunction. To investigate the effects of VEGF against human mature DCs, we investigated how VEGF affects mature DCs with regards to phenotype, induction of apoptosis, IL-12(p70) production and the antigen-presenting function evaluated by allogeneic mixed leukocyte reaction (allo-MLR). We generated monocyte-derived DCs matured with lipopolysaccharide, OK-432 or pro-inflammatory cytokine cocktails. As a result, VEGF treatment did not alter the mature DCs with regard to phenotype, IL-12(p70) production and induction of apoptosis. As a novel and important finding, VEGF inhibited the ability of mature DCs to stimulate allogeneic T cells. Furthermore, this VEGF-induced DC dysfunction was mainly mediated by VEGF receptor-2 (VEGF R2). These observations were confirmed by the findings that the VEGF-induced DC dysfunction was recovered by anti-human VEGF neutralizing mAb or anti-human VEGF R2 blocking mAb, and that placenta growth factor (PlGF), VEGF R1-specific ligand, did not have any effect against mature DCs. Some modalities aiming at reversing mature-DC dysfunction induced by VEGF will be needed in order to induce the effective antitumor immunity.





This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology in Japan.


  1. 1.
    Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689PubMedGoogle Scholar
  2. 2.
    Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755–1766PubMedGoogle Scholar
  3. 3.
    Ambe K, Mori M, Enjoji M (1989) S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63:496–503PubMedCrossRefGoogle Scholar
  4. 4.
    Chaux P, Favre N, Martin M, Martin F (1997) Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 72:619–624PubMedCrossRefGoogle Scholar
  5. 5.
    Chaux P, Moutet M, Faivre J, Martin F, Martin M (1996) Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74:975–983PubMedGoogle Scholar
  6. 6.
    Clauss M (1998) Functions of the VEGF receptor-1 (FLT-1) in the vasculature. Trends Cardiovasc Med 8:241–245PubMedCrossRefGoogle Scholar
  7. 7.
    Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W (1996) The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629–17634PubMedCrossRefGoogle Scholar
  8. 8.
    Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478PubMedCrossRefGoogle Scholar
  9. 9.
    Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125–133PubMedCrossRefGoogle Scholar
  10. 10.
    Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP (2005) Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174:215–222PubMedGoogle Scholar
  11. 11.
    Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K (2001) Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 80:99–110PubMedCrossRefGoogle Scholar
  12. 12.
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRefGoogle Scholar
  13. 13.
    Fujimoto T, Duda RB, Szilvasi A, Chen X, Mai M, O’Donnell MA (1997) Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 158:5619–5626PubMedGoogle Scholar
  14. 14.
    Furukawa T, Watanabe S, Kodama T, Sato Y, Shimosato Y, Suemasu K (1985) T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer 56:2651–2656PubMedCrossRefGoogle Scholar
  15. 15.
    Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166PubMedGoogle Scholar
  16. 16.
    Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRefGoogle Scholar
  17. 17.
    Gabrilovich DI, Ciernik IF, Carbone DP (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101–110PubMedCrossRefGoogle Scholar
  18. 18.
    Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–490PubMedGoogle Scholar
  19. 19.
    Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP (1996) Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 170:111–119PubMedCrossRefGoogle Scholar
  20. 20.
    Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398–5406PubMedGoogle Scholar
  21. 21.
    Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580PubMedCrossRefGoogle Scholar
  22. 22.
    Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL (2001) Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 24:162–171CrossRefGoogle Scholar
  23. 23.
    Ishida T, Oyama T, Carbone DP, Gabrilovich DI (1998) Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 161:4842–4851PubMedGoogle Scholar
  24. 24.
    Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572–577PubMedGoogle Scholar
  25. 25.
    Kiertscher SM, Luo J, Dubinett SM, Roth MD (2000) Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 164:1269–1276PubMedGoogle Scholar
  26. 26.
    Luo X, Liu L, Tang N, Lu KQ, McCormick TS, Kang K, Cooper KD (2005) Inhibition of monocyte-derived dendritic cell differentiation and interleukin-12 production by complement iC3b via a mitogen-activated protein kinase signalling pathway. Exp Dermatol 14:303–310PubMedCrossRefGoogle Scholar
  27. 27.
    Matsuda H, Mori M, Tsujitani S, Ohno S, Kuwano H, Sugimachi K (1990) Immunohistochemical evaluation of squamous cell carcinoma antigen and S-100 protein-positive cells in human malignant esophageal tissues. Cancer 65:2261–2265PubMedCrossRefGoogle Scholar
  28. 28.
    Miyake M, Taki T, Hitomi S, Hakomori S (1992) Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 327:14–18PubMedCrossRefGoogle Scholar
  29. 29.
    Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112–4118PubMedGoogle Scholar
  30. 30.
    Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23:263–272PubMedCrossRefGoogle Scholar
  31. 31.
    Ohm JE, Gabrilovich DI, Sempowski GD, Kisseleva E, Parman KS, Nadaf S, Carbone DP (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878–4886PubMedCrossRefGoogle Scholar
  32. 32.
    Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160:1224–1232PubMedGoogle Scholar
  33. 33.
    Pouyssegur J, Volmat V, Lenormand P (2002) Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64:755–763PubMedCrossRefGoogle Scholar
  34. 34.
    Puig-Kroger A, Relloso M, Fernandez-Capetillo O, Zubiaga A, Silva A, Bernabeu C, Corbi AL (2001) Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98:2175–2182PubMedCrossRefGoogle Scholar
  35. 35.
    Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N (1998) Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 78:1573–1577PubMedGoogle Scholar
  36. 36.
    Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97:785–791PubMedCrossRefGoogle Scholar
  37. 37.
    Shibuya M (2001) Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 33:409–420PubMedCrossRefGoogle Scholar
  38. 38.
    Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2004) Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 53:543–550PubMedCrossRefGoogle Scholar
  39. 39.
    Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, Ludewig B, Gillessen S, Merkle HP, Gander B, Groettrup M (2004) Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy. J Immunol Methods 287:109–124PubMedCrossRefGoogle Scholar
  40. 40.
    Zhou LJ, Tedder TF (1996) CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93:2588–2592PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Kousaku Mimura
    • 1
  • Koji Kono
    • 1
  • Akihiro Takahashi
    • 1
  • Yoshihiko Kawaguchi
    • 1
  • Hideki Fujii
    • 1
  1. 1.First Department of SurgeryUniversity of YamanashiChuo-cityJapan

Personalised recommendations